Renal Cell Carcinoma

During a Targeted Oncology case-based roundtable event, Scott Tykodi, MD, PhD, discussed the data supporting various treatment options for renal cell carcinoma with participants.

Updated findings from the phase 3 KEYNOTE-564 trial may further support adjuvant pembrolizumab as a new standard of care for patients with renal cell carcinoma with high risk of recurrence.

NeoAvAx trial results show that neoadjuvant avelumab/axitinib may be beneficial to patients with renal cell carcinoma.

A 3-year analysis of updated data from the phase 3 CheckMAte 9ER trial shows the better health-related quality of life outcomes for patients with advanced renal cell carcinoma on nivolumab plus cabozantinib.

A subgroup analysis of lenvatinib plus pembrolizumab showed similar results to the global population of patients with advanced renal cell carcinoma who participated in the phase 3 CLEAR trial.

Three immune cell-related factors appear to impact response or lack of response to treatment with nivolumab plus ipilimumab in patients with advanced or metastatic renal cell carcinoma.

In a final overall survival analysis of CheckMate 9ER, investigators saw a continued survival benefit with first-line nivolumab plus cabozantinib compared with sunitinib in the intention-to-treat patients with untreated clear cell metastatic or advanced renal cell carcinoma.

Tivozanib as first-line treatment showed noninferiority compared with other tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma in a real-world setting. This is an attractive option for patients due to tivozanib’s tolerable safety profile.

Lenvatinib in combination with pembrolizumab demonstrated clinical benefit in patients with advanced renal cell carcinoma regardless of their biomarker status.

Time to event end points and response rates were similar regardless of which first-line immunotherapy was administered, according to an analysis conducted by the International Metastatic Renal Cell Carcinoma Database Consortium

New data presented during the Genitourinary Cancers Symposium support the using cabozantinib after immunotherapy without new safety signals.

Patients with urothelial cancer whose tumors overexpress c-Met may benefit from this unique combination.

Cabozantinib administered in the neoadjuvant setting to patients with advanced renal cell carcinoma may be beneficial, but more research is needed to confirm.

Rana R. McKay, MD, discusses KEYNOTE-564 and the future of adjuvant immunotherapy in renal cell carcinoma.

In an interview with Targeted Oncology™, Naomi B. Haas, MD, discussed how the research has pivoted toward exploring neoadjuvant treatment for patients with renal cell carcinoma.

In an interview with Targeted Oncology, James Brugarolas, MD, PhD discussed promising updated survival data in metastatic renal cell carcinoma and investigational biomarkers to further advanced the field.

In an interview with Targeted Oncology, Nazli Dizman, MD, discussed the role of gut microbiome in cancer and speaks to her presentation given at IKCS.

During a Targeted Oncology case-based roundtable event, Robert J. Motzer, MD, discussed the results of several major trials of drug combinations in patients with renal cell carcinoma.

During a Targeted Oncology case-based roundtable event, Sumanta Kumar Pal, David I. Quinn, MD, MBBS, PhD, and participants discussed frontline therapy options for a patient with metastatic relapsed/refractory renal cell carcinoma.

During a Targeted Oncology Case-Based Roundtable event, Toni K. Choueiri, MD, discussed treatment options using immune checkpoint inhibitors in patients with advanced renal cell carcinoma.

The target number of patients with advanced renal cell carcinoma has been enrolled in the phase 3 CONTACT-3 trial, which aims to determine the efficacy and safety of cabozantinib combined with atezolizumab.

In an interview with Targeted Oncology, Sunil Sudarshan, MD, discussed the kidney cancer paradigm and opportunities to advance the field with new targets.

During a live virtual event, Ulka Vaishampayan, MBBS, discussed the results of the CLEAR trial of lenvatinib and pembrolizumab compared with sunitinib in first-line treatment of advanced RCC.

During a live virtual event, Sandy Srinivas, MD, discussed the tolerability of the tyrosine kinase inhibitor/immunotherapy combinations cabozantinib plus nivolumab and lenvatinib plus pembrolizumab, compared with the dual immunotherapy ipilimumab plus nivolumab.

Cristiane D. Bergerot, PhD, discusses how financial toxicity associated with renal cell carcinoma is impacting oncologists and their patients.